Hims & Hers Health (NYSE:HIMS) Rating Increased to Hold at Zacks Investment Research

Zacks Investment Research upgraded shares of Hims & Hers Health (NYSE:HIMSGet Rating) from a strong sell rating to a hold rating in a research report sent to investors on Wednesday morning, Zacks.com reports.

According to Zacks, “Hims & Hers Health Inc. is a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals, enabling medical care for numerous conditions related to mental health, sexual health, dermatology, primary care and more. Hims & Hers Health Inc., formerly known as Oaktree Acquisition Corp., is based in San Francisco. “

Other research analysts have also issued reports about the stock. Piper Sandler dropped their price objective on shares of Hims & Hers Health from $12.00 to $8.00 in a research note on Wednesday, February 23rd. Guggenheim started coverage on shares of Hims & Hers Health in a report on Wednesday, April 13th. They set a buy rating and a $10.00 price target on the stock. Deutsche Bank Aktiengesellschaft began coverage on shares of Hims & Hers Health in a research note on Thursday, March 10th. They issued a hold rating and a $7.00 price objective for the company. Finally, Citigroup reduced their price target on Hims & Hers Health from $9.00 to $6.00 in a report on Tuesday. Four equities research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat, Hims & Hers Health has a consensus rating of Buy and an average price target of $10.56.

Hims & Hers Health stock opened at $3.45 on Wednesday. Hims & Hers Health has a twelve month low of $2.72 and a twelve month high of $15.55. The company’s 50-day moving average price is $4.67 and its 200-day moving average price is $5.52.

Hims & Hers Health (NYSE:HIMSGet Rating) last issued its quarterly earnings data on Monday, May 9th. The company reported ($0.08) earnings per share for the quarter, hitting the consensus estimate of ($0.08). The company had revenue of $101.30 million for the quarter, compared to analysts’ expectations of $90.99 million. Hims & Hers Health had a negative return on equity of 22.41% and a negative net margin of 22.60%. The firm’s revenue for the quarter was up 93.7% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.14) earnings per share. On average, equities analysts forecast that Hims & Hers Health will post -0.32 earnings per share for the current fiscal year.

In other Hims & Hers Health news, Director Patrick Harrison Carroll sold 86,820 shares of the company’s stock in a transaction on Monday, February 28th. The stock was sold at an average price of $5.17, for a total transaction of $448,859.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Lynne Chou O’keefe sold 10,044 shares of the stock in a transaction on Thursday, March 17th. The shares were sold at an average price of $4.50, for a total value of $45,198.00. The disclosure for this sale can be found here. 43.70% of the stock is currently owned by corporate insiders.

Several hedge funds have recently added to or reduced their stakes in the business. Redpoint Management LLC purchased a new position in shares of Hims & Hers Health in the 4th quarter worth approximately $68,095,000. Forerunner Ventures Management LLC acquired a new position in shares of Hims & Hers Health during the fourth quarter worth $63,908,000. BlackRock Inc. increased its position in shares of Hims & Hers Health by 7.6% during the fourth quarter. BlackRock Inc. now owns 2,315,700 shares of the company’s stock worth $15,167,000 after purchasing an additional 163,791 shares in the last quarter. Renaissance Technologies LLC lifted its holdings in shares of Hims & Hers Health by 59.0% during the 1st quarter. Renaissance Technologies LLC now owns 1,682,600 shares of the company’s stock valued at $8,968,000 after purchasing an additional 624,127 shares during the last quarter. Finally, Morgan Stanley boosted its position in shares of Hims & Hers Health by 1,309.1% in the 3rd quarter. Morgan Stanley now owns 1,046,164 shares of the company’s stock worth $7,888,000 after purchasing an additional 971,920 shares in the last quarter. 57.22% of the stock is owned by institutional investors and hedge funds.

About Hims & Hers Health (Get Rating)

Hims & Hers Health, Inc operates a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals. The company offers a range of health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides prescription medication on a recurring basis and ongoing care from healthcare providers; and over-the-counter drug and device products, cosmetics, and supplement products, primarily focusing on wellness, sexual health and wellness, skincare, and hair care.

Read More

Get a free copy of the Zacks research report on Hims & Hers Health (HIMS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Hims & Hers Health (NYSE:HIMS)

Receive News & Ratings for Hims & Hers Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hims & Hers Health and related companies with MarketBeat.com's FREE daily email newsletter.